- Source: Alisertib
Alisertib (MLN8237) is an orally available , investigational, reversible, ATP-competitive, selective aurora A kinase inhibitor developed by Takeda. Inhibition of aurora A kinase A leads to disruption of mitotic spindle apparatus assembly, disruption of chromosome segregation, and inhibition of cell proliferation.
Takeda investigated alisertib as a treatment for relapsed or refractory peripheral T-cell lymphoma and development was paused in 2015 until Puma Biotechnology licensed global rights to alisertib from Takeda in 2022.
In clinical trials to date, alisertib has shown single agent activity and activity in combination with other cancer drugs in the treatment of many different types of cancers, including hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer and head and neck cancer.